Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF) Issues Earnings Results

Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF) posted its quarterly earnings data on Tuesday. The company reported $0.88 earnings per share for the quarter, Zacks reports. The firm had revenue of $770.90 million during the quarter.

Recordati Industria Chimica E Farmaceutica Stock Performance

Shares of OTCMKTS RCDTF remained flat at $56.95 during mid-day trading on Thursday. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.64 and a quick ratio of 1.16. The company has a 50 day simple moving average of $61.03 and a 200 day simple moving average of $63.90. Recordati Industria Chimica E Farmaceutica has a 1-year low of $49.00 and a 1-year high of $65.44. The stock has a market capitalization of $11.75 billion, a P/E ratio of 16.90 and a beta of 0.26.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the stock. Barclays raised shares of Recordati Industria Chimica E Farmaceutica from a “strong sell” rating to a “hold” rating in a report on Thursday, February 12th. Kepler Capital Markets raised shares of Recordati Industria Chimica E Farmaceutica from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, February 3rd. Two research analysts have rated the stock with a Strong Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Buy”.

About Recordati Industria Chimica E Farmaceutica

Recordati Industria Chimica e Farmaceutica is an Italy‐based international pharmaceutical company engaged in the research, development, manufacturing and commercialization of therapeutic products. Established in 1926, the company has built a diversified portfolio that includes proprietary drugs, generics and orphan medicines, with a particular emphasis on treatments for rare diseases. Recordati’s product range spans cardiovascular, urology, endocrinology, dermatology and oncology therapies, as well as specialized formulations for genetic and metabolic disorders.

The company’s historical roots date back nearly a century, when it began as a family‐owned enterprise in Milan.